Pfizer and Pain Therapeutics Announce FDA Complete Response Letter Received for REMOXY

Pfizer PFE and Pain Therapeutics, Inc. PTIE announced that a Complete Response Letter was received from the U.S. Food and Drug Administration on the resubmission to the new drug application for REMOXY Extended-Release Capsules CII. Pfizer is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with FDA around them.